A RETROSPECTIVE STUDY TO EVALUATE THE EFFICACY OF INJECTION AUGMENTIN IN COVID-19 PATIENTS WITH PNEUMONIA AT A TERTIARY CARE TEACHING HOSPITAL, TELANGANA

Abstract

Objective: Coronavirus is a single-stranded, enveloped, positive-sense RNA virus. It is responsible for the acute respiratory syndrome (SARS) and the disease is named COVID-19 by WHO. It is also called SARS-CoV-2. Pneumonia is one of the complications of COVID-19 disease. Patients with pneumonia admitted to General Hospital were treated with Augmentin. Augmentin is a broad-spectrum antibacterial that has been available for clinical use in a wide range of indications for over 20 y and is now used primarily in the treatment of respiratory tract infections. The main objective of our study is to evaluate the efficacy of Augmentin in COVID-19 patients with pneumonia in terms of beneficial effects after treatment. Methods: The present study was a retrospective, observational, record-based study of the case sheets of COVID-19 patients with pneumonia. The statistical analysis was done using paired t-test. Results: In our institution COVID-19 patients with pneumonia were treated with Tablet FAVIRAPIR and Injection AUGMENTIN. The results were calculated using paired t-test and the P-value was<0.0001, which is significant as it is less than 0.05. Therefore, the post-treatment outcome results showed a significant improvement in disease reduction. Conclusion: The study concludes that the empirical treatment of COVID-19 patients with pneumonia using an appropriate antibiotic reduces further deterioration of patients with pneumonia due to complications and also protects the patients from acquired infections during the hospital stay.